PMID- 20137761
OWN - NLM
STAT- MEDLINE
DCOM- 20100325
LR  - 20190608
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 48
IP  - 2
DP  - 2010 Feb
TI  - Effect of cilostazol on platelet aggregation in patients with non-ST elevation 
      acute coronary syndrome.
PG  - 93-102
AB  - AIMS: The optimal antithrombotic regimen for non-ST elevation acute coronary 
      syndrome(NSTEACS) has not yet been defined and the risk of ischemic events 
      remains high in these patients. We aimed to evaluate the effect of cilostazol on 
      agonist induced platelet aggregation and serum plasminogen activator 
      inhibitor-1(PAI-1) in the patients with NSTEACS administered along with the 
      standard antiplatelet regimen. PATIENTS AND METHODS: 40 patients of NSTEACS 
      presenting within 72 h of onset of symptoms were randomized to cilostazol or 
      placebo in 1 : 1 ratio, in whom a conservative treatment strategy was adopted. 
      Cilostazol 100 mg b.i.d was administered within 12 h of hospital admission for 7 
      days along with standard doses of aspirin and clopidogrel. The primary end points 
      were effect on agonist-induced platelet aggregation and serum PAI-1 levels after 
      7 days of treatment. Safety and clinical outcome assessment were also done at 7 
      and 30 days. RESULTS: Patients in the triple therapy group showed significant 
      decrease in the ADP (25.5 +/- 27.4 vs. 5.6 +/- 8.4; p = 0.003) and collagen (24.9 
      +/- 25.5 vs. 11.7 +/- 11; p = 0.04) induced percentage platelet aggregation after 
      7 days of treatment compared to the dual therapy group. There was no significant 
      change in levels of serum PAI-1 (50.30 +/- 10.17 ng/ml vs. 53.47 +/- 14.08 ng/ml; 
      p = 0.42). The composite of recurrent ischemia, myocardial infarction, need for 
      intervention and death occurred in 4 patients in the cilostazol group compared to 
      7 in the placebo group at the end of 30 days of follow-up (p = 0.48). CONCLUSION: 
      Cilostazol has additional platelet aggregation inhibition action in patients with 
      NSTEACS along with aspirin and clopidogrel.
FAU - Pattanaik, S
AU  - Pattanaik S
AD  - Department of Pharmacology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh-160 012, India.
FAU - Malhotra, S
AU  - Malhotra S
FAU - Sharma, Y P
AU  - Sharma YP
FAU - Ahluwalia, J
AU  - Ahluwalia J
FAU - Bhalla, A
AU  - Bhalla A
FAU - Pandhi, P
AU  - Pandhi P
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Tetrazoles)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/physiopathology
MH  - Adult
MH  - Aged
MH  - Aspirin/therapeutic use
MH  - Cilostazol
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plasminogen Activator Inhibitor 1/blood
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacology/therapeutic use
MH  - Tetrazoles/adverse effects/*pharmacology/therapeutic use
MH  - Ticlopidine/analogs & derivatives/therapeutic use
EDAT- 2010/02/09 06:00
MHDA- 2010/03/26 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/03/26 06:00 [medline]
AID - 7297 [pii]
AID - 10.5414/cpp48093 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2010 Feb;48(2):93-102. doi: 10.5414/cpp48093.